The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist
Abstract
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis. DATA SOURCES: MEDLINE and Excerpta Medica online databases were searched to identify published reports. STUDY SELECTION: Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US. DATA EXTRACTION: Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared. DATA SYNTHESIS: Domperidone, a peripheral dopamine 2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood–brain barrier, reports of central nervous system adverse effects, such as dystonic reactions, are rare. CONCLUSIONS: Domperidone is a unique gastrokinetic and antiemetic drug. Because of its favorable safety profile, domperidone appears to be an attractive alternative to metoclopramide. In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Laduron, P. M., & Leysen, J. E. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90198-9 · Cited by 396
Metoclopramide: Pharmacology and Clinical Application
ALBIBI, R., & McCALLUM, R. W. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-86 · Cited by 348
Koch, K. L., Stern, R. M., Stewart, W. R., & Vasey, M. W. (1989) · PubMed · Cited by 324
Metoclopramide: Pharmacology and clinical application
Bullard, D. E. (1983) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(83)90196-9 · Cited by 295
Brogden, R. N., Carmine, A. A., Heel, R. C., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198224050-00002 · Cited by 280
Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy
Horowitz, M., Harding, P. E., Chatterton, B. E., Collins, P. J., & Shearman, D. J. C. (1985) · Digestive Diseases and Sciences · doi:10.1007/bf01318363 · Cited by 236
GARDINER, P. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91078-7 · Cited by 228
Dopamine as A Possible Neurotransmitter in Gastric Relaxation
Valenzuela, J. E. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80051-0 · Cited by 205
Hughes, A. J., Bishop, S., Kleedorfer, B., Turjanski, N., Fernandez, W., Lees, A. J., & Stern, G. M. (1993) · Movement Disorders · doi:10.1002/mds.870080208 · Cited by 204
Cited by
Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R., & De Ponti, F. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01867.x · Cited by 291
Li, Z. S., Schmauss, C., Cuenca, A., Ratcliffe, E., & Gershon, M. D. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4720-05.2006 · Cited by 276
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope?
Georgescu, D., Ancusa, O., Georgescu, L., Ionita, I., & Reisz, D. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s106284 · Cited by 138
A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis
Sugumar, A., Singh, A., & Pasricha, P. J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.065 · Cited by 102
Metadata
- Authors
- Barone, J. A.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1999-04
- Volume
- 33
- Issue
- 4
- Pages
- 429-440
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2164198919
- Cited by
- 259
- References
- 67
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist. https://app.cochat.ai/papers/10.1345/aph.18003
- The paper
- Barone, J. A. (1999). Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.18003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.